156 related articles for article (PubMed ID: 36574187)
1. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation.
Okada K; Uemura K; Okamoto W; Sumiyoshi T; Shintakuya R; Otsuka H; Serikawa M; Ishii Y; Arihiro K; Takahashi S
Clin J Gastroenterol; 2023 Apr; 16(2):283-288. PubMed ID: 36574187
[TBL] [Abstract][Full Text] [Related]
2. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
3. Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma.
Servin-Rojas M; Fong ZV; Fernandez-Del Castillo C; Ferrone CR; Lee H; Lopez-Verdugo F; Qiao G; Rocha-Castellanos DM; Lillemoe KD; Qadan M
Surgery; 2024 Feb; 175(2):471-476. PubMed ID: 37949693
[TBL] [Abstract][Full Text] [Related]
4. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
[TBL] [Abstract][Full Text] [Related]
5. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
6. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline
Pimenta JR; Ueda SKN; Peixoto RD
Case Rep Oncol; 2020; 13(2):904-910. PubMed ID: 32884538
[TBL] [Abstract][Full Text] [Related]
7. Response in
Campoverde LE; Batalini F; Bulushi Y; Bullock A
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487638
[TBL] [Abstract][Full Text] [Related]
8. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.
Ozaki K; Hayashi H; Ikuta Y; Masuda T; Akaboshi S; Ogata K; Matumoto K; Ogawa K; Kamio T; Baba H; Takamori H
Clin J Gastroenterol; 2019 Dec; 12(6):603-608. PubMed ID: 30993652
[TBL] [Abstract][Full Text] [Related]
9. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
10. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Golan T; Barenboim A; Lahat G; Nachmany I; Goykhman Y; Shacham-Shmueli E; Halpern N; Brazowski E; Geva R; Wolf I; Goldes Y; Ben-Haim M; Klausner JM; Lubezky N
Ann Surg Oncol; 2020 Oct; 27(10):3963-3970. PubMed ID: 32314163
[TBL] [Abstract][Full Text] [Related]
11. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
13. An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.
Prete AA; Procaccio L; Bergamo F; Rasola C; Nappo F; Zagonel V; Lonardi S
Curr Oncol; 2022 Jan; 29(2):544-550. PubMed ID: 35200549
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX.
Höhn P; Braumann C; Nöpel-Dünnebacke S; Munding J; Uhl W; Luu AM
Visc Med; 2021 Mar; 37(2):149-153. PubMed ID: 33981756
[TBL] [Abstract][Full Text] [Related]
15. A case of metachronous oligo-hepatic and peritoneal metastases of pancreatic cancer with a favorable outcome after conversion surgery combined with perioperative sequential chemotherapy.
Tohyama T; Tanno Y; Murakami T; Hayashi T; Fujimoto Y; Takehara K; Seshimo K; Fukuhara R; Omori M; Matsumoto T
Clin J Gastroenterol; 2024 Apr; 17(2):371-381. PubMed ID: 38291249
[TBL] [Abstract][Full Text] [Related]
16. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Vreeland TJ; McAllister F; Javadi S; Prakash LR; Fogelman DR; Ho L; Varadhachary G; Aloia TA; Vauthey JN; Lee JE; Kim MP; Katz MHG; Tzeng CD
Pancreas; 2019 Jul; 48(6):837-843. PubMed ID: 31210666
[TBL] [Abstract][Full Text] [Related]
17. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
Wang H; Mao C; Li N; Sun L; Zheng Y; Xu N
Medicine (Baltimore); 2019 Oct; 98(40):e17443. PubMed ID: 31577767
[TBL] [Abstract][Full Text] [Related]
18. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
20. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]